Search News + Media

The Reid R. Sacco Adolescent & Young Adult (AYA) Cancer Program at Tufts Medical Center was created 7 years ago and the team has shared the creation and model of care in a recent publication.

Tufts Medical Center announced today that it has become the first center in New England to use the drug Jelmyto (UroGen Pharma, Inc.) for treatment of upper tract urothelial cancer (UTUC), a malignancy found in the kidney lining or the ureter, the thin tube connecting the bladder to the kidneys.

The financial impact of cancer, during treatment as well as during the years of long-term follow-up care, is experienced by many patients and survivors. AYAs may be further negatively impacted as they are historically the largest proportion of uninsured or underinsured patients.

When Justin Williams, 28, walked into his local emergency room in October of 2018, he was shocked to learn that the pain he was experiencing was not from the minor car accident he was in the day before. The physicians suspected cancer.